The following link is a fact sheet regarding the role of Occupational Therapy in treating sensory processing disorder: https://www.aota.org/-/media/corporate/files/aboutot/professionals/whatisot/cy/fact-sheets/factsheet_sensoryintegration.pdf
   Although Ayres initially developed her assessment tools and intervention methods to support children with sensory integration and processing challenges, the theory is relevant beyond childhood.Sensory integration therapy is driven by four main principles:
Just right challenge (the child must be able to successfully meet the challenges that are presented through playful activities)
Adaptive response (the child adapts their behavior with new and useful strategies in response to the challenges presented)
Active engagement (the child will want to participate because the activities are fun)
Child directed (the childs preferences are used to initiate therapeutic experiences within the session)Serious questions have been raised as to the effectiveness of this therapy particularly in medical journals where the requirements for a treatment to be effective is much higher and developed than its occupational therapy counter parts which often advocate the effectiveness of the treatment.
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate. Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain. It is marketed by Alcon under the tradename Durezol. Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis


== References ==